A new study shows that most COVID-19 boosters boost immunity, although no shot wins.

The first study to directly compare COVID-19 boosters shows that most shots improve immune responses in fully vaccinated people, but there are no clear “wins” to help deliver make decision.

SVB Leerink analysts told investors on Friday: “In terms of the ‘best’ boost, there are no definite winners, but there are some losers.

NS research, published on Thursday in The Lancet, evaluated the booster shots in around 2,900 people in the UK

It compares combinations of full and half doses of vaccines developed by BioNTech SE
+ 3.17%

and Pfizer Inc.
+ 2.32%
Novavax Inc.
and Valneva SE
as well as a full dose of AstraZeneca

Johnson & Johnson
+ 1.46%
and Moderna Inc.
+ 1.73%


(Trials resumed in June; since then, CureVac has scrapped development of its first-generation COVID-19 vaccine candidate. Valneva and Novavax are still seeking a vaccine license. in the UK. Other injections have received permission there.)

UK clinical trial participants were all vaccinated with either AstraZeneca’s vaccine or Comirnaty, BioNTech and Pfizer vaccines. The study only included people over the age of 30 who had never tested positive for the virus.

In summary, nearly all of the vaccines in the study produced an immune response among the participants, although the type of response varied. (People who were initially immunized with the AstraZeneca shot did not produce a different immune response to the same injection as the booster.)

According to SVB Leerink analysts, a full dose of Moderna vaccine produces the highest antibody titres. (In both the US and UK, Moderna’s booster is allowed as a half-dose.) Novavax’s injection is best tolerated, in terms of side effects. J&J spurred T cells to proliferate more than other cells – a point of particular concern now that there are concerns that the omicron variant may reduce the protective ability of the antibody. Comirnaty, analysts told investors, is the “old-fashioned” of the team, based on how it generates both antibody and T-cell responses. And, ultimately, as the saying goes, the injection of AstraZeneca does not work as much as a booster for people who have already been vaccinated with the same vaccine.

The study’s authors recommend that policymakers and national immunization committees “establish criteria for selecting which booster vaccines to use in their populations.”

America is not doing this, at least for the moment.

Mixing and matching COVID-19 shots have been approved by the Food and Drug Administration since October. That means, for example, people who have received a single dose of J&J vaccine can choose between a second J&J shot or a booster dose of Comirnaty or Moderna vaccines.

The decision to allow mixing and matching of vaccines in the United States stems from the fact that preliminary research, also known as preprint, is conducted by the National Institutes of Health. That study showed that antibody levels were highest from the Moderna enhancer, then Pfizer, and then J&J; however, the study was not designed to compare vaccine combinations.

For Americans looking for guidance on which booster shots to give, the US is no longer telling people what is the best booster based on their primary series and is instead recommending Encourage people to sign up for whatever injections they choose.

Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention, said Oct. 22. “We won’t be specific about which preferences, saying: ‘I understand that most people will complete it. are mostly good with the original vaccine they have and may express a preference, very much, for the initial series of vaccines they receive… There may be some people who may prefer a vaccine request is different than the one they received, and current CDC recommendations now make that possible. ”

That said, federal health officials in the US continue to recommend that people who were vaccinated before June get a booster shot.

“There is every reason to believe that if you are vaccinated and boosted that you will have at least some degree of cross-protection, most likely against,” said Dr. Anthony Fauci, medical adviser to the president. against severe disease, even against the omicron variant,” Dr Anthony Fauci, the president’s chief medical adviser, said at a news conference on Friday.

Read more of MarketWatch’s coverage of COVID-19 boosters:

Those who have shot J&J’s COVID-19 can receive boosters. Which should they take?

Here’s why COVID-19 booster shots are good for business

Allowing people to mix COVID-19 vaccines could cut Pfizer and Moderna revenue next year

https://www.marketwatch.com/story/a-new-study-finds-that-most-covid-19-vaccines-boost-immunity-though-there-is-no-winning-shot-11638554711?rss=1&siteid=rss A new study shows that most COVID-19 boosters boost immunity, although no shot wins.


Inter Reviewed is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – admin@interreviewed.com. The content will be deleted within 24 hours.

Related Articles

Back to top button